The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna reported a surprise third-quarter ... US FDA pauses Novavax's trial of combo COVID-flu shot on safety concerns The U.S. Food and Drug Administration has put on hold a trial of Novavax's ...

Moderna Inc. delivered better-than-expected profit and sales in the third quarter after an early start to sales of this season’s Covid boosters. The company’s latest Covid shot was approved ...

He added that the company expected to hit the lower end of this sales range if Moderna's market share for COVID vaccines remained the same and there was no uptick in sales of its RSV shot.

Shares of Moderna (NASDAQ:MRNA ... attributed the sales growth mainly to the earlier launch of the updated COVID-19 shot that led to higher sales in the U.S. market. “With FDA approval granted ...